Brofaromine in major depressed patients: a controlled clinical trial versus imipramine and open follow-up of up to one year.
In an 8-week controlled double-blind clinical trial with a total of 216 patients Brofaromine was found to be superior to Imipramine with regard to efficacy (Hamilton Depression Scale, von Zerssen self-rating scale, global evaluation) and tolerability (adverse experiences, global evaluation). Mean daily dosages were 93.1 mg/day in the Brofaromine group and 92 mg/day in the Imipramine Group. No tyramine reduced diet had to be observed. Long-term efficacy and tolerability also proved to be good in an open follow-up in the Brofaromine group.
Möller
H J
HJ
Department of Psychiatry, University of Bonn, FRG.
Volz
H P
HP
D000328:Adult; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007099:Imipramine / Q000009:adverse effects / Q000627:therapeutic use*; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D010555:Personality Inventory; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use*
D008996:Monoamine Oxidase Inhibitors; D010880:Piperidines; C038213:brofaromine; D007099:Imipramine